Ocugen is trading at $0.99, down 5%, after shareholders adjourned a special-meeting vote on increasing authorized common stock by 250 million shares. - The meeting will reconvene on October 5, 2026, to allow additional proxy solicitation. - The proposal raises potential dilution concerns. - Broader market weakness also weighed on risk appetite. Biotech strength provided limited support, while no stronger positive company catalyst was identified for September 23, 2026.